Anaplastic Large Cell Lymphoma Occurring in Association With Breast Implants

Taylor, Clive R.; Siddiqi, Imran; Brody, Garry S.

doi:10.1097/pai.0b013e318266476c

Cited by 74 publications

(14 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epithelial membrane antigen is overexpressed in several cancers, including breast cancer, and ALK (OMIM 105590) is a fusion gene present in up to 70% of systemic ALCL . T-cell antigen expression is variable, with the most frequently expressed markers being CD4, CD3, CD45, and CD2, in decreasing order . Molecular analysis shows monoclonal T-cell receptor ( TCR ) γ gene rearrangement .…”

Section: Resultsmentioning

confidence: 99%

“…40 T-cell antigen expression is variable, with the most frequently expressed markers being CD4, CD3, CD45, and CD2, in decreasing order. 36,41 Molecular analysis shows monoclonal T-cell receptor (TCR) γ gene rearrangement. 27 The tumor cell layer on the surrounding capsule can be thin and discontinuous, leading to false negative with capsule histology.…”

Section: Assessment and Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Breast Implant–Associated Anaplastic Large Cell Lymphoma

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Assessment and Diagnosismentioning

confidence: 99%

Breast Implant–Associated Anaplastic Large Cell Lymphoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…However, it is not clear if it was true negative percent), and CD2 (30 percent). 13 Expression of CD5, CD7, or CD8 is rare. 13 In our case, the lymphoma cells were positive for CD3 (subset), CD4, CD7, and CD43,…”

Section: Discussionmentioning

confidence: 99%

“…Our case highlights that generous sampling is important in the investigation of patients with suspected breast implantassociated ALCL. Moreover, if diagnosis is undetermined following initial investigation, additional evaluation is necessary to achieve a final diagnosis of, or confidently exclude, breast implant-associated ALCL, when there is a high clinical index of suspicion.Morphologically, the tumor is comprised of large, pleomorphic cells with abundant cytoplasm, sometimes horseshoe-shaped nuclei, and prominent nucleoli 3,13. By immunohistochemistry, breastimplant-associated ALCL demonstrates strong and uniform membranous expression of CD30 and lacks ALK expression.…”

mentioning

confidence: 99%

Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Case Report

Vadehra

Cai

Bhuyan

et al. 2021

JHOR

View full text Add to dashboard Cite

Breast implant-associated anaplastic large cell lymphoma (ALCL) is a recently recognized type of T-cell lymphoma that can develop following breast implants, with morphologic and immunophenotypic features indistinguishable from those of ALK-negative ALCL. Here we report a case of a 58-year-old woman with a history of subglandular silicone implants placed for bilateral breast augmentation 25 years ago, who presented with bilateral breast pain and was found to have bilateral Baker Grade III capsular contracture, and heterogenous fluid collection centered near the left third costochondral articulation, a suspicious left chest wall lesion, and left axillary lymphadenopathy on imaging. A left axillary lymph node core biopsy and an aspiration of the fluid were performed, and no malignant cells were identified. The patient underwent bilateral removal of breast implants and total capsulectomies. Microscopic examination of the capsule surrounding the left breast implant revealed large pleomorphic tumor cells in a fibrinous exudate. By immunohistochemistry, the tumor cells were found to be positive for CD3 (subset), CD4, CD7, CD30 (strong and uniform), and CD43, and negative for CD2, CD5, CD8, and ALK1, supporting the diagnosis of breast implant-associated ALCL. No lymphoma cells were identified in the right breast capsule, confirmed by CD30 stain. Breast implant-associated ALCL is a very rare disease that can develop many years after breast implant placement. Proper evaluation with breast imaging and pathologic workup is essential to confirm the diagnosis in suspected cases. Our case highlights that adequate sampling is important in the investigation of patients with suspected breast implant-associated ALCL.

show abstract

“…The first case of BIA-ALCL worldwide was reported in 1997, 2 and a growing number of related literature have been published since. 3 4 5 6 7 It was recognized as a distinct clinical entity of ALCL by the World Health Organization in 2016 and recognized by the U.S. Food and Drug Administration more recently. 8 9…”

mentioning

confidence: 99%

Comprehensive Evaluation of the Current Knowledge on Breast Implant Associated-Anaplastic Large Cell Lymphoma

2022

View full text Add to dashboard Cite

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a recently spotlighted T-cell origin non-Hodgkin's lymphoma with an increasing incidence of over 800 cases and 33 deaths reported worldwide. Development of BIA-ALCL is likely a complex process involving many factors, such as the textured implant surface, bacterial biofilm growth, immune response, and patient genetics. As the incidence of BIA-ALCL is expected to increase, it is important for all surgeons and physicians to be aware of this disease entity and acquire thorough knowledge of current evidence-based guidelines and recommendations. Early detection, accurate diagnosis, and appropriate treatment are the foundations of current care.

show abstract

Anaplastic Large Cell Lymphoma Occurring in Association With Breast Implants

Cited by 74 publications

References 15 publications

Breast Implant–Associated Anaplastic Large Cell Lymphoma

Breast Implant–Associated Anaplastic Large Cell Lymphoma

Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Case Report

Comprehensive Evaluation of the Current Knowledge on Breast Implant Associated-Anaplastic Large Cell Lymphoma

Contact Info

Product

Resources

About